Vice Chairman of the Board of Directors, Chief Executive Officer

Ben Cheng

Mr. Cheng is an asset management executive, focusing on transformative opportunities across various sectors. With extensive experience in venture capital and private equity, Mr. Cheng as CEO of C Capital has played a pivotal role in high-profile investments, including CASETiFY, the fastest-growing global tech accessories brand; XiaoPeng (NYSE: XPEV), a leading Chinese electric vehicle manufacturer; Animoca Brands, a multinational blockchain technology; NOTHING, a UK based consumer electronics manufacturer; Lalamove, a prominent Chinese on-demand logistics firm. He is also a board member of various Nasdaq and HK-listed companies. Prior to C Capital, Mr. Cheng honed his expertise as an investment banker at Bank of America Merrill Lynch and Standard Chartered Bank, where he was involved in landmark transactions such as the US$3.3 billion take-private of WuXi PharmaTech, Temasek’s US$5.7 billion investment in Watson’s and the US$2.1 billion acquisition of ING's insurance business in Hong Kong, Macau and Thailand.


Vice Chairman of the Board of Directors, Chief Executive Officer

Ben Cheng

Mr. Cheng is an asset management executive, focusing on transformative opportunities across various sectors. With extensive experience in venture capital and private equity, Mr. Cheng as CEO of C Capital has played a pivotal role in high-profile investments, including CASETiFY, the fastest-growing global tech accessories brand; XiaoPeng (NYSE: XPEV), a leading Chinese electric vehicle manufacturer; Animoca Brands, a multinational blockchain technology; NOTHING, a UK based consumer electronics manufacturer; Lalamove, a prominent Chinese on-demand logistics firm. He is also a board member of various Nasdaq and HK-listed companies. Prior to C Capital, Mr. Cheng honed his expertise as an investment banker at Bank of America Merrill Lynch and Standard Chartered Bank, where he was involved in landmark transactions such as the US$3.3 billion take-private of WuXi PharmaTech, Temasek’s US$5.7 billion investment in Watson’s and the US$2.1 billion acquisition of ING's insurance business in Hong Kong, Macau and Thailand.